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Abstract: Histone deacetylases (HDACs) are enzymes that act on histone proteins to remove the acetyl group and thereby regulate the
chromatin state. HDACs act not only on histone protein but also nonhistone proteins that are key players in cellular processes such
as the cell cycle, signal transduction, apoptosis, and more. “Classical” HDACs have been shown to be promising targets for anticancer
drug design and development. However, the selectivity of HDAC inhibitors for HDAC isoforms remains the motivation of current
research in this field. Here, we explored Class I HDACs and HDAC6 by sequence alignment and structural superimposition, catalytic
channel extraction, and identification of critical residues involved in HDAC catalysis. Based on the general pharmacophore features
of known HDAC inhibitors, we developed a library of compounds by scaffold hopping on a fragment hit identified via structurebased virtual screening of the molecular fragment library retrieved from the Otava database. Molecular docking assay revealed five of
these compounds to have increased potency and selectivity for HDACs 1 and 2. Furthermore, their predicted absorption, distribution,
metabolism, elimination, and toxicity (ADMET) properties were consistent with those of drug-like compounds. With further modelingbased and experimental investigations, we believe that these findings may offer additional potential HDAC inhibitors with improved
selectivity.
Key words: Scaffold hopping, molecular docking, ADMET analysis, potent and isoform-selective HDAC inhibitors, anticancer agents

1. Introduction
The human genome is packaged into chromatin inside
the nucleus of the cell. The basic structural unit of
chromatin is nucleosome, containing approximately 146
base pairs of DNA wrapped around a histone octamer:
two copies each of histones H2A, H2B, H3, and H4.
The lysine and arginine residues of histone protein are
subject to an array of posttranslational modifications
including acetylation, methylation, phosphorylation, and
ubiquitination. The N-terminal region of the histones
(“the histone tails”) plays a major role in transcriptional
regulation upon acetylation and deacetylation of various
lysine residues within these regions. The acetylation
state of histones is reversibly regulated by two classes of
enzymes, histone acetyltransferases (HATs) and histone
deacetylases (HDACs) (Roth et al., 2001; Richmond and
Davey, 2003; Khorasanizadeh, 2004; Kouzarides, 2007).
There are 18 genes encoding HDAC family members in
the human genome. These are grouped into four classes
based on their homology to yeast. Classes I, II, and IV
are Zn2+-dependent, whereas Class III contains NAD+
(nicotinamide adenine dinucleotide)-dependent enzymes.
* Correspondence: yelekci@khas.edu.tr

Class I consists of HDACs 1, 2, 3, and 8 isoforms. They
share sequence homology with yeast reduced potassium
dependency-3 (RPD3) and are localized in the nucleus
of the cells (Gregoretti et al., 2004; Yang et al., 2005; Li
et al., 2007; Bannister and Kouzarides, 2011; Zentner
and Henikoff, 2013). Class II HDACs share sequence
homology with the yeast histone deacetylases 1 (Hda1)
and are further divided into Class IIa (HDACs 4, 5, 7,
and 9) and Class IIb (HDACs 6 and 10). Class II HDACs
are primarily localized in the cytoplasm, but can be
shuttled between the cytoplasm and nucleus depending
on the phosphorylation status. Class IV consists of only
HDAC11, localized in the nucleus. Class III comprises
seven members, SIRT1 through SIRT7, sharing sequence
homology with yeast silent information regulator-2 (Sir2)
protein (Fischle et al., 2001; Verdin et al., 2003; Yang and
Grégoire, 2005).
HDACs are promising therapeutic targets in anticancer
drug design and development due to their roles in the
pathogenesis of various cancers. Aberrant expressions
of HDACs in diverse cancer cell lines and tumor tissues
have been reported (Bolden et al., 2006). HDAC1 was
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overexpressed in prostate (Halkidou et al., 2004) and
breast cancers (Zhang et al., 2005), hepatocellular
carcinoma via systemic regulation of mitotic effectors
(Xie et al., 2012), and impaired spermatogenesis and
testicular cancer (Cacan et al., 2014). Despite functional
redundancy between HDACs 1 and 2, HDAC2 was shown
to be independently implicated in various types of human
cancers. The upregulation of tumor-promoting genes,
such as those of tyrosine kinases, mediators of cell cycle
progression and angiogenic factors, by HDAC2 mutant
cells in human cancer has been reported (Ropero et al.,
2008). HDAC2 inhibition in pancreatic cancer cell lines
induced apoptosis by sensitization of the tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL)
(Schüler et al., 2010). HDAC3 and other class I HDACs
are highly expressed in colon cancer (Wilson et al., 2006;
Godman et al., 2008; Spurling et al., 2008; Rajendran et al.,
2011). HDAC6 was found to be expressed more in lowgrade and high-grade ovarian carcinomas (Bazzaro et al.,
2008) and oral squamous cell carcinoma (Sakuma et al.,
2006). Both HDAC6 and HDAC8 were found to be highly
expressed and implicated in the invasion and progression
of breast cancer cells (Park et al., 2011). HDAC8 has
been implicated in neuroblastoma, T-cell lymphoma, and
acute myeloid leukemia (Oehme et al., 2009). Global loss
of monoacetylation at lysine number 16 of histone H4 is
the common hallmark of human cancer cells (Fraga et al.,
2005).
Thus, a number of HDAC inhibitors are in clinical
trials after the FDA’s approval of vorinostat, a pan-HDAC
inhibitor for the treatment of cutaneous T-cell lymphoma,
in 2006; romidepsin, also for peripheral T-cell lymphoma
in 2011; belinostat, for the treatment of patients with
relapsed or refractory peripheral T-cell lymphoma, in
2014 (Bolden et al., 2006); and, recently, panobinostat, for
the treatment of multiple myeloma, in 2015. Mocetinostat
is another HDAC inhibitor with remarkable potency
against HDAC1 compared with HDACs 2, 3, and 11,
currently in clinical trial for the treatment of leukemia or
myelodysplastic syndromes (Garcia-Manero et al., 2008).
Entinostat and tacedinaline show high selectivity for

Class I HDACs 1–3 and moderate selectivity for HDAC8
and are in clinical trials for the treatment of advanced
solid tumors (Prakash et al., 2001; Pili et al., 2011). Other
selective HDAC inhibitors are in different stages of trials
for the treatment of various solid and nonsolid cancers.
For example, MRLB-223 is in preclinical trial as a selective
inhibitor of HDACs 1 and 2 (Newbold et al., 2013). BG45
is also in preclinical trial as a selective inhibitor of HDAC3
(McConkey et al., 2012). Tubacin and rocilinostat (ACY1215) are in preclinical and phase IIa trials, respectively,
as HDAC6 selective inhibitors (Haggarty et al., 2003;
Cosenza et al., 2014). PCI-34051 is in preclinical trial as a
selective inhibitor of HDAC8.
HDAC inhibitors are potent inducers of cell cycle
arrest in transformed cells and their subsequent death via
apoptotic, autophagic, and reactive oxygen species (ROS)mediated pathways. They are also found to decrease cell
migration and angiogenesis by targeting nonhistone
proteins including transcription factors (p53, E2F c-Myc,
NF-κB), retinoblastoma protein (pRb), estrogen receptor
alpha (ER α), androgen receptor (AR), hypoxia-inducible
factor 1 alpha (HIF-1α), signaling mediators (Stat3,
Smad7), MyoD, chaperons (HSP90), α-tubulin, β-catenin,
DNA repair proteins (Ku70) and many more (Singh et al.,
2010; Kim and Bae, 2011; Peng and Seto, 2011).
Generally, HDAC inhibitors have their pharmacophore
containing three features: a capping group for surface
recognition, a hydrocarbon linker, and a zinc binding
domain, as shown in Figure 1 (Mottamal et al., 2015). In an
attempt to discover more potent and selective inhibitors,
researchers vary one or all of these features to achieve
desired potency and selectivity. A computer-aided scaffold
replacement method can be used, wherein a portion of the
molecule could be replaced, or a group might be added
to achieve a particular polar or steric interaction that
might enhance the binding affinity (Langdon et al., 2010).
In addition, novel inhibitors can be predicted in silico by
probing a database of a large chemical library. For instance,
both structure-based and ligand-based virtual screenings
have been applied for identification of selective HDAC
inhibitors (Liu et al., 2010; Park et al., 2010; Wang et al.,

Figure 1. Structure of vorinostat (SAHA) showing the general pharmacophore features of
HDAC inhibitors. The capping group, linker, and zinc binding domain are indicated.
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2013) with the most recent study by Huang et al. (2016),
in which virtual screening and experimental validation
of HDAC8 inhibitors was performed. Other modeling
approaches including pharmacophore modeling (Chen
et al., 2008), flexible docking, and three-dimensional
QSAR (3D-QSAR) (Nair et al., 2012) have been used for
the identification of selective HDAC inhibitors. Here, we
attempted to design potent and isoform-selective HDAC
inhibitors by a combined approach of structure-based
virtual screening, scaffold hopping, ADMET prediction,
and molecular docking. We believe that subtle differences
in the HDAC active site amino acids could be exploited to
achieve isoform selectivity.
2. Materials and methods
2.1. Protein setup
The following crystal structures of human histone
deacetylases were retrieved from the Protein Data Bank
(PDB): 4BKX (“The structure of HDAC1 in complex with

the dimeric ELM2-SANT domain of MTA1 from the
NuRD complex”) (Millard et al., 2013); 4LXZ (“Structure
of human HDAC2 in complex with SAHA”) (Lauffer et al.,
2013); 4A69 (“Structure of HDAC3 bound to corepressor
and inositol tetraphosphate”) (Watson et al., 2012); 5EDU
(“Crystal structure of human histone deacetylase 6 catalytic
domain 2 in complex with trichostatin A); and 1T64
(“HDAC8 in complex with the inhibitor TSA”) (Somoza et
al., 2004). All water molecules and cocrystallized ligands
were removed from enzyme structures. The noninteracting
ions were also removed, leaving Zn2+, as it is critical for the
catalytic activity of the enzymes. Missing hydrogen atoms
were added on the basis of the protonation state of the
titratable residues at a pH of 7.4 using the Biovia Discovery
Studio 4.0 molecular modeling program.
2.2. Sequence alignment and structural superimposition
From the PDB crystal structure, amino acid sequences
of Class I HDACs and HDAC6 were aligned using
Biovia Discovery Studio 4.0 (Figures 2A and 2B) and

Figure 2A. Multiple sequence alignment of Class I HDACs and HDAC6. The degree of sequence conservation is indicated in
the intensity of blue coloration. Identity is indicated in dark blue, similarity in moderate and light blue, and difference in white.
The amino acids in the catalytic channels of these isoforms are similar even though the overall sequence identity was 7.2% and
sequence similarity 15.6%. HDAC6 has additional structural motif aligned to the gap.

Figure 2B. Multiple sequence alignment of class I HDACs. The degree of sequence conservation is indicated in the intensity of blue
coloration. Identity is indicated in dark blue, similarity in moderate and light blue, and difference in white. The amino acids in the
catalytic channels of Class I isoforms are similar; the overall sequence identity is 33.1% and sequence similarity is 57.8%. HDAC8
shows slight sequence variation compared with the rest of the class members.
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their corresponding 3D structures were superimposed
(Figure 3A). Calculated from the structural alignment,
root mean square displacement (RMSD) values and
number of overlapped residues (NRES) with one another
are compared in Figure 3B. In addition, the conserved
amino acid residues that are involved in HDAC catalysis
were also aligned (Table 1). Moreover, to gain insight
into the evolutionary relationship among these isoforms,
phylogenetic trees were constructed from multiple
sequence alignment using Basic Local Alignment Search
Tool (BLAST), available via the National Center for
Biotechnology Information (NCBI) database (Figure 4).
2.3. Structure-based virtual screening and ligand setup
Virtual screening is a process of screening a large
library of compounds to identify pharmacologically
active compounds. It is automated to quickly evaluate
a series of compounds based on their biological activity

against a target protein. It is usually used to identify an
initial compound (hit) for further optimization. In this
study, structure based-virtual screening of the molecular
fragment library retrieved from the Otava database was
conducted using the AutoDock Vina (PyRx) program.
The highest scoring fragment (Otava id: 5683342)
showed desirable activity against HDAC3. The library
was screened against HDAC3 because, according to our
phylogenetic analysis of the HDAC isoforms under study,
HDAC3 shares sequence similarity with Class I HDACs
and, to a relatively low extent, with HDAC6. Based on
the general pharmacophore features of HDAC inhibitors,
structural modifications were made by scaffold hopping
in which various synthetically feasible groups were added
and the core structure replaced to achieve particular polar,
hydrophobic, or steric interactions around the entrance
and deep catalytic channels (Figure 5). These interactions

Figure 3. Structural superimposition and alignment of Class I HDACs and HDAC6. HDAC6 shares a conserved
catalytic domain with Class I HDACs; HDAC6 has an additional structural motif aligned to the gap (purple)
(A). RMSD and the number of overlapped residues (NRES) with respect to one another are indicated in yellow
and blue colors, respectively (B).
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Table 1. Superimposition of common residues among class I
HDACs and HDAC6 that are components of the charge-relay
system of HDAC catalysis.
HDAC1

HDAC2

HDAC3

HDAC8

HDAC6

HIS140

HIS145

HIS134

HIS142

HIS573

HIS141

HIS146

HIS135

HIS143

HIS574

HIS178

HIS183

HIS172

HIS180

HIS614

ASP176

ASP181

ASP170

ASP178

ASP610

PHE205

PHE210

PHE200

PHE208

ASP612

ASP264

ASP266

ASP259

ASP267

ASP706

TYR303

TYR308

TYR298

TYR306

TYR745

were targeted to enhance the binding affinity and selectivity
considering the subtle difference in the amino acids at the
highly conserved active sites of the HDAC isoforms. Their
3D geometries were optimized and saved in pdb format in
the Biovia Discovery Studio program.

2.4. Drug-likeness and ADMET prediction
ADMET properties constitute the pharmacokinetic profile
of a drug molecule and are very essential in evaluating its
pharmacodynamic activities. For a compound to be druglike it has to pass the ADMET test. Nowadays, these ADMET
properties can be predicted in silico based on the structure
of a compound. In this study, the ADMET properties were
calculated using ADMET Predictor (Simulation Plus).
These are: S+logP (octanol-water partition coefficient, log
P); S+logD (octanol-water distribution coefficient, log D);
MlogP (Moriguchi model of log P); RuleOf5 (“computational
filter for oral absorption in human identical to Lipinski’s
‘Rule of Five’”) (Owens and Lipinski, 2003; Lipinski, 2004;
Ridder et al., 2011); molecular weight (mw); number of
hydrogen bond donors (HBD) and acceptors (HBA); and
topological polar surface area (TPSA). Other ADMET
properties, which include probability of crossing the blood–
brain barrier P(BBB+), probability for human intestinal
absorption P(HIA+), Caco-2 permeability, and aqueous
solubility (Aq. Sol.), were predicted using the admetSAR
server (Cheng et al., 2012) (Table 2).

Histone deacetylase 8 [Homo sapiens]
Histone deacetylase 3
[Homo sapiens]
Histone deacetylase 1
[Homo sapiens]
Histone deacetylase 2
[Homo sapiens]

Histone deacetylase 4
[Homo sapiens]
Histone deacetylase 9
[Homo sapiens]
Histone deacetylase 5
[Homo sapiens]
Histone deacetylase 7 [Homo sapiens]
Histone deacetylase 6
[Homo sapiens]
Histone deacetylase 10
[Homo sapiens]

Figure 4. Phylogenetic tree constructed using NCBI BLAST for HDAC1 relatives. The tree shows that the closest relative of
HDAC1 is HDAC2; HDAC3 shares ancestral origin with HDACs 1 and 2, while HDAC8 is a distant relative of HDACs 1 and
2 with 2 nodes and shares an evolutionary relationship with HDAC3 at a distance of 1 node. The closest relative of HDAC6 is
HDAC10; HDAC6 also shares ancestral origin with HDACs 4, 5, 7, and 9.
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Figure 5. The designed compounds KA_025 through KA_037 by scaffold hopping on a common molecular fragment (otava id: 5683342) identified via structure-based virtual
screening.
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Table 2. Predicted drug-like and ADMET properties using ADMET Predictor program and AdmetSAR server.
Compound MlogP S+logP S+logD RuleOf5 MWt(Da) HBA T_PSA(Å²) HBD P(BBB+) P(HIA+)

Aq. Sol. Caco-2
(LogS) Perm. (cm/s)

KA_025

3.33

4.056

4.06

0

329

3

39.07

0

0.9935

0.9784

–3.6906 1.4943

KA_026

2.51

2.471

2.47

0

332

4

42.31

0

0.9882

0.9784

–3.2093 1.4537

KA_027

2.96

2.957

2.02

0

368

5

59.38

0

0.9031

1

–3.4582 0.9243

KA_028

2.2

3.943

3.94

0

340

4

53.17

1

0.9791

1

–3.4364 0.8404

KA_029

3.21

3.206

1.58

0

342

5

62.4

1

0.9575

1

–3.6458 1.0199

KA_030

1.68

3.449

3.45

0

356

5

51.54

0

0.9159

1

–3.7513 1.0197

KA_031

2.946

3.755

3.755

0

323.4

3

29.54

0

0.9943

1

–3.6109 1.505

KA_032

1.981

2.694

2.694

0

326.4

4

41.57

1

0.9824

0.965

–3.5817 1.3993

KA_033

0.62

0.929

0.929

0

262.3

4

49.41

1

0.9443

0.9272

–2.4127 1.4715

KA_034

0.589

2.105

2.105

0

277.3

4

59.16

1

0.9758

1

–2.6094 1.0467

KA_035

0.97

3.564

3.564

0

331.3

4

59.16

1

0.9758

1

–2.6094 1.0467

KA_036

3.99

3.989

2.81

0

322

3

37.05

2

0.7739

0.9225

–3.1637 1.0026

KA_037

2.323

2.719

2.7

0

322.4

5

67.25

2

0.8496

0.9682

–2.5174 0.9262

2.5. Molecular docking assay
The AutoDockTool (ADT) program (version 1.5.6rc3)
was used to generate the molecular docking input files.
Gasteiger partial charges were assigned to each atom
to generate a grid parameter file (gpf) and a docking
parameter file (dpf). The program uses an Amber-based
semiempirical force field with a molecular mechanics
model for enthalpic contributions (van der Waals and
hydrogen bonding) and an empirical force field model
for changes in entropy on binding (Weiner et al., 1984;
MacKerell and Banavali, 2000; de Magalhães et al., 2004).
For validation purposes, and to assess the quality of
the prepared protein structures, a series of known HDAC
inhibitors were docked into the catalytic channels of the
HDAC enzymes under study. These established inhibitors
include the approved drugs (vorinostat and belinostat,
romidepsin) and those in clinical trials (mocetinostat,
entinostat, tacedinaline). Their estimated free energy of
binding and the inhibition constant were consistent with
the experimental values reported in the literature, except for
HDAC8, against which the binding affinities of entinostat
and tacedinaline were not well reproduced in this study.
Energy grid boxes with dimensions of 55, 55, and 55 Å for
HDACs 1, 2, and 8 and 65, 65, and 65 Å for HDACs 3 and
6 were centered near Zn2+ and covered the entire binding
site and its neighboring residues. A Lamarckian genetic
algorithm was used to search for ligand conformation in
the catalytic channel of the enzymes. For each ligand, 20
independent runs were performed and the distinct ligand
conformers generated were docked randomly into the
binding pocket of these HDAC enzymes. The program

randomly assigned torsion angles to rotatable bonds. For
each docking, 15 million energy evaluations were allowed.
3. Results
3.1. Sequence and structural analysis
The whole sequence alignment revealed that amino acid
residues in the catalytic channels of Class I HDACs and
HDAC6 were similar even though the overall sequence
identity is 7.2% and sequence similarity 15.6%. The low
percentage of sequence identity and similarity resulted
from a structural element present in HDAC6 in addition
to the conserved catalytic domain it shares with Class I
HDACs. Class I HDACs share 33.1% sequence identity
and 57.8% sequence similarity. The HDACs’ active site
is conserved, especially among Class I HDACs 1–3, with
sequence identity and similarity of 60.5% and 81.7%,
respectively. HDACs 1 and 2 share the highest sequence
identity of 93.5% and similarity 97.8% .
3.2. Binding affinity
The potency and selectivity of our designed compounds,
denoted KA_025 through KA_037, are compared with
those of known HDAC inhibitors in Table 3 and the
selectivity index of the selective compounds among them
is given in Table 4. KA_025, KA_026, and KA_027 were
found to have the highest binding affinity among the
designed inhibitors and showed selectivity for HDACs 1
and 2. KA_029 was selective for HDAC1 only and KA_036
showed modest selectivity for HDAC2 only. KA_028,
KA_030 through KA_035, and KA_037 showed selectively
for neither a specific isoform nor a particular group of
HDACs. KA_025, KA_026, and KA_027 were as selective
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Table 3. Estimated free energy of binding of KAs against Class I HDACs and HDAC6 compared with known HDAC
inhibitors. The compounds are color-coded: known HDAC inhibitors (blue); HDACs 1 and 2 selective (green); HDAC1selective (yellow); HDAC2-selective (orange); and nonselective inhibitors (light purple).
HDAC1

HDAC2

HDAC3

HDAC8

HDAC6

Compound

ΔG (kcal/mol)

ΔG (kcal/mol)

ΔG (kcal/mol)

ΔG (kcal/mol)

ΔG (kcal/mol)

Vorinostat

–8.45

–8.64

–8.32

–8.42

–8.55

Belinostat

–9.62

–8.89

–9.44

–8.68

–8.02

Romidepsin

–8.22

–8.76

–8.44

–7.99

–7.34

Entinostat

–9.82

–9.86

–10.62

–7.16

–7.65

Tacedinaline

–8.62

–8.10

–9.08

–7.36

–7.82

Mocetinostat

–9.89

–9.44

–9.76

–6.44

–7.32

KA_025

–10.45

–10.31

–8.99

–8.53

–8.46

KA_026

–10.20

–9.82

–8.88

–8.64

–8.62

KA_027

–10.34

–10.21

–9.01

–8.93

–8.93

KA_028

–9.72

–9.52

–8.87

–8.39

–7.94

KA_029

–9.95

–8.02

–8.1

–7.71

–8.00

KA_030

–9.18

–8.41

–8.29

–7.90

–7.94

KA_031

–9.41

–8.98

–9.09

–8.43

–8.6

KA_032

–9.05

–8.35

–8.82

–7.66

–8.29

KA_033

–8.23

–8.14

–8.15

–7.70

–7.72

KA_034

–8.60

–7.79

–8.01

–8.22

–7.56

KA_035

–8.12

–7.33

–7.60

–7.72

–7.22

KA_036

–7.60

–9.03

–7.9

–7.81

–7.73

KA_037

–7.92

–8.11

–8.13

–7.81

–8.08

Table 4. Selectivity index of the potential selective inhibitors of HDACs 1 and 2 compared to HDACs 3, 6, and 8.
HDAC1

HDAC2

HDAC3

HDAC8

HDAC6

Selectivity Index

Ki1(nM)

Ki2(nM)

Ki3(nM)

Ki8(nM)

Ki6(nM)

Ki2/Ki1

Ki3/Ki1

Ki8/Ki1

Ki6/Ki1

KA_025

21.85

27.49

384

678

689

1.26

17.57

31.03

31.53

HDAC1&2

KA_026

33.28

63.43

396

465.02

483.53

1.91

11

13.97

14.53

HDAC1&2

KA_027

26.25

32.82

246.21

282.7

284.26

1.25

9.34

10.77

10.83

HDAC1&2

KA_029

51.13

1271

1240

2220

1286

24.9

24.25

43.42

25.15

HDAC1

Ki1/Ki2

Ki3/Ki2

Ki8/Ki2

Ki6/Ki2

KA_036

2680

238.67

1619

1890

2160

11.23

6.78

7.92

9.05

Compounds

for HDAC1 as they were for HDAC2 and are therefore
termed HDAC1- and HDAC2-selective.
3.3. Binding mode analysis
KA_025, KA_026, and KA_027 spanned the catalytic
channels of HDACs 1 and 2 in a similar manner. Although
fewer interactions were observed with HDAC2, the
predominant interactions (π-stacked, π-π T-shaped,
π-alkyl, van der Waals, hydrogen bond) were common in
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Selectivity

HDAC2

both isoforms’ complexes. Another selective compound,
KA_029 has an additional interaction (metal-acceptor)
between Zn2+ and oxygen of the sulfonyl group coupled
with -π sulfur interactions between the same parties.
However, such interactions were not observed with
HDAC2 despite catalytic channel similarity between these
isoforms. This might be due to conformational differences
that allowed for binding of this same compound in a
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different mode. Interestingly, KA_036 fit in the catalytic
channels of HDACs 1 and 2 with different orientations
despite repeated docking runs to ascertain the lowest
energy conformations of the compound. Consequently,
their set of interactions differed and so did binding affinity,
being higher with HDAC2.
3.4. ADMET analysis
According to ADMET prediction, these compounds
were drug-like, having passed “the rule of 5” and other
pharmacokinetic tests. All the indices were found to
be within the acceptable range for drug candidacy. An
important measure of drug-likeness, TPSA is an index that
shows the likelihood of transporting a molecule through
cell membranes. It allows for the prediction of human
intestinal absorption and blood–brain barrier penetration,
among others. The descriptor sensitivity curves of S+logP
in response to the TPSA of KA_025, KA_029, and KA_36
are shown is shown in Figure 6. The slope of the curve
was correlated with the feasible value reflecting the
hydrophilicity/hydrophobicity of the compounds. All
of the compounds were predicted to have TPSA < 100,
indicating their likelihood of crossing the lipid bilayer.
Other ADMET properties estimated including aqueous
solubility (LogSw) and Caco-2 (human epithelial colorectal
adenocarcinoma) permeability were within the normal
range of a drug-like molecule. Aqueous solubility of a drug
molecule is a very important ADMET property influencing
absorption and transport of a drug molecule in the body.
The quantitative structure property relationship (QSPR)
has been successfully applied to relate 150 drug and
organic molecules to their respective aqueous solubility
(Ghasemi and Saaidpour, 2007). Caco-2 permeability
is another crucial property reflecting gastrointestinal
permeability by measuring the rate of transport of a drug
molecule across the Caco-2 cell line. It has been studied in
vitro (van Breemen and Li, 2005; Volpe et al., 2007; Volpe,
2011) and in silico (Nordqvist et al., 2004; Ponce et al.,
2005; Akamatsu et al., 2009; Paixão et al., 2010; Singh et
al., 2015). The predicted Caco-2 permeability and aqueous
solubility of our designed compounds were in agreement
with the widely-followed “Jorgensen Rule-of-Three”, which
states that “the aqueous solubility measured as logS should
be greater than –5.7, the apparent Caco-2 cell permeability
should be faster than 22 nm/s and the number of primary
metabolites should be less than 7; these limits are based on
the properties of 90% of 1700 oral drugs” (Di and Kerns,
2016).
4. Discussion
Our designed selective inhibitors, particularly KA_025,
KA_026, and KA_027, showed improved potency
and selectivity compared with all the known HDAC
inhibitors used in this study. Compared with the approved

nonselective HDAC inhibitors, vorinostat, belinostat,
and romidepsin, and well-studied HDAC inhibitors in
clinical trials, entinostat, tacedinaline, and mocetinostat,
both the potency and selectivity were improved in silico,
with the exception of entinostat, which showed higher
binding affinity for HDAC3 (∆G = –10.62 kcal/mol) (Table
3). Entinostat binds selectively to the Class I HDACs
1–3 and with a relatively moderate affinity to HDAC8,
with significant antitumor efficacy, currently in clinical
development for treatment of human colorectal cancer
lines (Bracker et al., 2009). Similarly, tacedinaline is another
selective inhibitor of Class I HDACs 1–3 with modest
activity against HDAC8, shown to inhibit the growth of
lung and breast cancers, lymphoblastic leukemia, and
more (Mottamal et al., 2015). This moderate selectivity of
both entinostat and tacedinaline for HDAC8 was not well
reproduced in our study; therefore, the binding affinities
of these inhibitors for HDAC8 presented in Table 3 should
be considered with caution. Mocetinostat is 2- to 10fold more selective for HDAC1 than HDACs 2, 3, and 11
(Boumber et al., 2011). These known selective inhibitors
were used as reference compounds to guide the selection
of our potent and selective inhibitors. The thresholds for
potency and selectivity index were >9.00 kcal/mol and ≥7,
respectively. The increased potency of KA_025, KA_026,
and KA_027 may be in part attributed to the carbonyl
oxygen presence in their linker group involved in hydrogen
bond interactions, specifically with TYR for HDAC1 and
HIS for HDAC2.
Generally, deacetylation of substrate occurs through a
“charge-relay system” consisting of two adjacent histidine
residues, two aspartic residues, and one tyrosine residue
in the deep catalytic pocket of HDACs (Table 1). When a
cation binds near the bottom of the pocket, it is coordinated
by two additional aspartates and one histidine and also by
a water molecule (Finnin et al., 1999). HDAC inhibitors
function by chelating the Zn2+, making the charge-relay
system dysfunctional. In the complexes of HDAC1 with
KA_025, KA_026, and KA_027, zinc was involved in
metal-acceptor interaction via the carbonyl oxygen of the
linker group; however, such interaction was not observed
in the complexes of HDAC2 with these compounds,
rather, van der Waals interaction was seen. Moreover, the
two adjacent histidine residues (HIS140 and HIS141 for
HDAC1 and HIS145 and HIS146 for HDAC2) and two
aspartic acid residues (ASP176 and ASP264 for HDAC1)
and one (ASP183 in HDAC2) were found to be involved
in interactions with KA_025, KA_026, and KA_027. These
findings were consistent with a study by Fournel et al.
(2002), in which sulfonamide anilides were shown to have
antiproliferative activity against human tumor without
chelating zinc from the active site of HDACs. Here, although
it is not clear what exactly brought about the selectivity of
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Figure 6. Sensitivity curve of exponential of S+LogP versus topological surface area of compounds
KA_025 (A), KA_029 (B), and KA_036 (C).

KA_025, KA_026, and KA_027 for HDACs 1 and 2 given
their similarity in structure with the other nonselective
inhibitors, we speculate that their unique carbonyl group
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near the cap might have changed the set of interactions in
the deep active site of the enzymes, consequently leading to
their selectivity for HDACs 1 and 2 (Figures 7–9).
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Figure 7. 3D (left) and 2D (right) representations of HDAC1 active site containing KA_025; zinc ion interacted
with carbonyl oxygen via metal-acceptor interaction (A). 3D (left) and 2D (right) representations of HDAC2 active
site containing KA_025 (B). KA_025 bound HDACs 1 and 2 with different binding modes and yet showed similar
affinity. Other types of nonbond interactions are indicated in their respective colors in the 2D scheme.

Of all the selective inhibitors designed here, KA_029
interacted with HDAC1 in the typical way that HDAC
inhibitors bind zinc-containing HDACs. Zinc was chelated
by one sulfonyl oxygen via metal-acceptor interaction and
the catalytically essential amino acid residues, HIS140,
HIS141, HIS178, ASP176, ASP264, and TR303, also
interacted mainly with the sulfonyl group (Figure 10). This
result is partly in agreement with findings by Noor et al.
(2015), in which zinc was shown to be chelated via sulfonyl
oxygen of Class I selective inhibitor.
In the HDAC2-KA_036 complex, various noncovalent
interactions including van der Waals, π-sulfur, π-alkyl, π-π
stacked, and 4 hydrogen bonds were formed. Interestingly,

the oxygen bridge of the linker group engaged TRY308
via one hydrogen bond interaction (Figure 11). TRY308
is a component of the charge-relay system of HDAC2
catalysis. These interactions added up to contribute to the
overall stability of the complex.
These findings are especially important given the lack
of specificity of the many HDAC inhibitors in clinical use
and trials. It is particularly challenging to achieve isoform
selectivity among Class I HDACs 1–3 due to their highly
conserved active site. It is believed that the continued
identification of isoform-specific inhibitors will remain
a major challenge to HDAC inhibitor development.
Theoretically, the isoform-specific HDAC inhibitors might
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Figure 8. 3D (left) and 2D (right) representations of HDAC1 active site containing KA_026; zinc ion interacted
with sulfonyl oxygen via metal-acceptor interaction (A). 3D (left) and 2D (right) representations of HDAC2 active
site containing KA_026 (B). KA_026 bound HDACs 1 and 2 with similar binding modes and binding affinity.
Other types of nonbond interactions are indicated in their respective colors in the 2D scheme.

be more effective if the specific HDAC is a component
of a repressive complex that is crucial for tumorigenesis
(Lane and Chabner, 2009). In this study, Class I HDACs
and HDAC6 were targeted considering findings that
histone acetylation is thought to be primarily regulated by
HDACs 1–3, whereas the acetylation of tubulin and Hsp90
is specifically regulated through HDAC6 (Newbold et al.,
2013). These provide strong rationales for the selective
inhibition of these individual isoforms in cancer. The
search for isoform-selective HDAC inhibitors is being
carried out using both computational and experimental
approaches. Computational procedures are indispensable
components of rational drug design. Thus, we believe
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that these predicted HDAC inhibitors can be potentially
isoform-selective, warranting further modeling-based
and experimental studies towards validation of their
bioactivity.
In conclusion, potent and selective inhibitors of
HDACs 1 and 2 were designed by a combination of
structure-based virtual screening and scaffold hopping
using pharmacophore information of known HDAC
inhibitors. Their binding affinities and modes were
examined by molecular docking assay. They were also
found to be drug-like according to ADMET prediction
using two independent ADMET prediction tools. We
therefore believe that these findings may offer additional
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Figure 9. 3D (left) and 2D (right) representations of HDAC1 active site containing KA_027; zinc ion interacted
with carbonyl oxygen via metal-acceptor interaction (A). 3D (left) and 2D (right) representations of HDAC2
active site containing KA_027 (B). KA_027 bound HDACs 1 and 2 with similar binding modes and binding
affinity. Unique π-sigma interaction with HDAC1 and π-cation interaction with HDAC2 were observed. Other
types of nonbond interactions are indicated in their respective colors in the 2D scheme.
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Figure 10. 3D (upper) and 2D (lower) representations of HDAC1 active site
containing KA_029. The types of nonbond interactions are indicated in their
respective colors in the 2D scheme; zinc ion (in ash spheres) interacted with sulfonyl
oxygen via metal-acceptor interaction.
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Figure 11. 3D (upper) and 2D (lower) representations of HDAC2 active site containing
KA_036. The types of nonbond interactions are indicated in their respective colors in
the 2D scheme.
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potential HDAC inhibitors with isoform selectivity or
provide scaffolds for further optimization towards the
discovery of selective HDAC inhibitors for cancer therapy.
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